1. Home
  2. SOS vs BCDA Comparison

SOS vs BCDA Comparison

Compare SOS & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SOS

SOS Limited

SELL

Current Price

$3.57

Market Cap

4.3M

Sector

Finance

ML Signal

SELL

Logo BioCardia Inc.

BCDA

BioCardia Inc.

SELL

Current Price

$0.78

Market Cap

15.7M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SOS
BCDA
Founded
2004
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3M
15.7M
IPO Year
2005
2009

Fundamental Metrics

Financial Performance
Metric
SOS
BCDA
Price
$3.57
$0.78
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $15.50
AVG Volume (30 Days)
★ 303.1K
83.3K
Earning Date
10-07-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $479,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.17
$0.66
52 Week High
$2.08
$1.80

Technical Indicators

Market Signals
Indicator
SOS
BCDA
Relative Strength Index (RSI) 96.34 34.32
Support Level $1.00 N/A
Resistance Level N/A $1.03
Average True Range (ATR) 0.09 0.10
MACD 0.22 -0.01
Stochastic Oscillator 91.12 34.17

Price Performance

Historical Comparison
SOS
BCDA

About SOS SOS Limited

SOS Ltd is a multifaceted company that leverages the power of data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing and other Hosting services. The company has single reporting segment: Commodity trading and generates key revenue is generated from Commodity trading.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: